Humana (NYSE:HUM) announced that its board has authorized a stock repurchase plan, which authorizes the company to repurchase $3.00 billion in shares on Thursday, December 14th, EventVestor reports. This repurchase authorization authorizes the insurance provider to purchase shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Shares of Humana (HUM) traded down $5.63 during mid-day trading on Friday, reaching $250.61. 1,353,500 shares of the company’s stock were exchanged, compared to its average volume of 1,375,474. Humana has a twelve month low of $186.25 and a twelve month high of $264.56. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 0.35. The company has a market cap of $36,606.47, a P/E ratio of 21.86, a price-to-earnings-growth ratio of 1.76 and a beta of 0.88.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.27 by $0.12. Humana had a net margin of 3.49% and a return on equity of 15.99%. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $13.41 billion. During the same period in the prior year, the firm posted $3.18 EPS. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. research analysts predict that Humana will post 11.63 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Thursday, December 28th. Humana’s payout ratio is 12.59%.

Several research firms have weighed in on HUM. BMO Capital Markets lifted their price target on shares of Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, November 10th. Royal Bank of Canada reissued a “sector perform” rating and set a $242.00 target price (down from $245.00) on shares of Humana in a research report on Thursday, November 9th. BidaskClub downgraded shares of Humana from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Jefferies Group reissued a “hold” rating and set a $257.00 target price on shares of Humana in a research report on Friday, October 13th. Twelve analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $256.30.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with's FREE daily email newsletter.